Literature DB >> 8453550

Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma.

J W Gamel1, I W McLean, J B McCurdy.   

Abstract

BACKGROUND: For certain types of cancer, resection alone rarely achieves a cure, but patients nevertheless tend to have a prolonged survival before they die of the tumor. For other types of cancer, the opposite scenario prevails, suggesting that those biologic mechanisms that allow a curative resection are not identical to those that determine survival time among uncured patients.
METHODS: The multivariate log-normal model can be used to detect the association of cured fraction and median survival time of patients with specific prognostic covariates. This model was applied to survival data from 2892 patients with intraocular melanoma who were treated by enucleation.
RESULTS: This analysis showed that large tumor size and pleomorphic nucleoli within the tumor were associated independently with a low probability of cure and short median survival time. Advanced patient age and mixed cell type, however, were highly associated with only a short median survival time.
CONCLUSIONS: For patients with intraocular melanoma treated only by enucleation, the median survival time is not modulated by the same biologic factors that determine the likelihood of a curative resection.

Entities:  

Mesh:

Year:  1993        PMID: 8453550     DOI: 10.1002/1097-0142(19930401)71:7<2299::aid-cncr2820710721>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  DNA ploidy pattern in choroidal melanoma: correlation with survival. A flow cytometry study on archival material.

Authors:  P Toti; G Greco; P Mangiavacchi; A Bruni; M L Palmeri; P Luzi
Journal:  Br J Ophthalmol       Date:  1998-12       Impact factor: 4.638

2.  Expression of VLA-2, VLA-3, and alpha(v) integrin receptors in uveal melanoma: association with microvascular architecture of the tumour and prognostic value.

Authors:  G Anastassiou; H Schilling; S Djakovic; N Bornfeld
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

3.  Tumor vascularity and hematogenous metastasis in experimental murine intraocular melanoma.

Authors:  H E Grossniklaus
Journal:  Trans Am Ophthalmol Soc       Date:  1998

4.  "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma.

Authors:  I W Reiniger; U C Schaller; C Haritoglou; R Hein; A K Bosserhoff; A Kampik; A J Mueller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-05-20       Impact factor: 3.117

5.  DNA flow cytometry in uveal melanoma: the effect of pre-enucleation irradiation.

Authors:  C Mooy; K Vissers; G Luyten; A Mulder; T Stijnen; P de Jong; F Bosman
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

6.  The biology of haematogenous metastasis in human uveal malignant melanoma.

Authors:  I W McLean
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

7.  Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma.

Authors:  I Kaiserman; I Anteby; I Chowers; E Z Blumenthal; I Kliers; J Pe'er
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

Review 8.  An alternative hypothesis for observed mortality rates due to metastasis after treatment of choroidal melanomas of different sizes.

Authors:  James J Augsburger; Zélia M Corrêa; Nikolaos Trichopoulos
Journal:  Trans Am Ophthalmol Soc       Date:  2007

9.  Measurement of human choroidal melanoma xenograft volume in rats using high-frequency ultrasound.

Authors:  Rod D Braun; Kerry S Vistisen
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

10.  Inhibition of a vascular ocular tumor growth by IL-12 gene transfer.

Authors:  Adriana Albini; Gianfranco Fassina; Massimo Nicolò; Raffaella Dell'Eva; Roberta Vené; Rosaria Cammarota; Massimo Barberis; Douglas M Noonan
Journal:  Clin Exp Metastasis       Date:  2007-07-25       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.